INTRODUCTION
The immunosuppressive thiopurines azathioprine (AZA) and mercaptopurine (MP) are commonly used in the management of both moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC), and have proven efficacy in maintaining remission of these inflammatory bowel diseases (IBD). 1, 2 Both AZA and MP need to undergo various intracellular transformations to form active metabolites of which 6-tioguanine nucleotides (6-TGN) and 6-methylmercaptopurine ribonucleotides (6-MMPR) are considered the most important. Thiopurine S-methyltransferase (TPMT) plays a pivotal role in the balance of 6-TGN and the 6-MMPR formation. 3 Up to a quarter of the patients discontinue thiopurine therapy due to adverse drug reactions (ADRs) within the first 3 months of treatment, of which gastrointestinal intolerance (i.e. nausea and vomiting) and hepatotoxicity are the most common. [4] [5] [6] [7] Thiopurine-induced hepatotoxicity may occur in up to 10% of patients. 6 Dose-related hepatotoxicity and subsequent therapy withdrawal have been related to high steady-state 6-MMPR metabolite concentrations. 4, [8] [9] [10] Hepatotoxicity may also be observed in patients with low 6-MMPR concentrations, thus the exact role of 6-MMPR in predicting hepatotoxicity remains unclear. 11 Since alternative therapeutic options are limited in IBD, early identification of patients at risk of thiopurine-related ADRs is important to improve thiopurine effectiveness.
We aimed to assess the predictive value of 6-MMPR metabolite concentrations, determined 1 week after thiopurine initiation, for the development of thiopurineinduced hepatotoxicity, but also gastrointestinal complaints and general malaise, during the first 20 weeks of therapy in IBD patients.
MATERIALS AND METHODS

Study design and outcome definition
The study was performed among the first 270 consecutive included patients of the 'Thiopurine response Optimization by Pharmacogenetic testing in Inflammatory bowel disease Clinics' (TOPIC) trial, a large randomisedcontrolled trial in 769 IBD patients evaluating the efficacy and cost-effectiveness of pre-treatment TPMT genotyping ( Figure 1 ). Written informed consent was obtained from all participating patients. The TOPIC study is registered at clinicaltrials.gov (NCT00521950). For a detailed description of the study design and patient selection of the TOPIC trial, we refer to Coenen et al. 12 Patients meeting the inclusion criteria were randomly assigned to either standard thiopurine treatment (AZA 2-2.5 mg/kg/day or MP 1-1.5 mg/kg/day) or a dose regimen based on the TPMT genotype. The decision to use MP or AZA was made by the clinician. Patients of the intervention group carrying a genetic TPMT variant were treated with 50% (TPMT heterozygous) or 0-10% (TPMT homozygous) of the standard thiopurine dose, according to Dutch guidelines. 13 All patients were clinically followed up for 20 AE 6 weeks after treatment initiation. Haematological and biochemical safety parameters were measured 1 week before initiation and at least at weeks 1, 2, 4, 6, 8 and 20 after initiation of thiopurine therapy.
For this study, blood samples for 6-MMPR and 6-TGN measurements were collected 1 week (~7 AE 1 day) after thiopurine initiation (T1). The thiopurine metabolite concentrations were measured after the follow-up period.
Thiopurine dose adjustments were defined as thiopurine dose escalation or reduction. Any decision regarding dose adjustments or discontinuation of thiopurine therapy due to ADRs or thiopurine intolerance was made by the responsible physician and was subsequently recorded. Hepatotoxicity, considered as acute hepatocellular hepatitis, was defined by elevations from baseline of alanine aminotransaminase (ALT) up to at least twice the upper limit of the reference values (2N) or by a ratio of alanine aminotransaminase and alkaline phosphatase (ALP) ≥5.
Nausea, vomiting and/or anorexia reported by the patients were registered as gastrointestinal complaints by the clinician.
Thiopurine-induced hepatotoxicity, gastrointestinal complaints and general malaise were evaluated in relation to 6-MMPR and 6-TGN concentrations assessed at T1. Therefore, a prior-to-treat TPMT genotype-guided dose regimen in the course of the TOPIC trial did not interfere with our primary outcome.
The design of this study is depicted in Figure 1 .
6-MMPR and 6-TGN metabolite measurement 6-MMPR and 6-TGN concentrations were determined in erythrocytes by a modified high performance liquid chromatography method of Lennard and Singleton. Blood samples for thiopurine metabolite measurement were immediately stored in the refrigerator (2-8°C) to secure metabolite stability and subsequently sent to the Department of Clinical Pharmacy and Toxicology of the Zuyderland Medical Centre (Sittard-Geleen, The Netherlands), where erythrocytes were washed, counted and stored at À20°C until required.
Measurement of TPMT enzyme activity TPMT enzyme activity was measured in red blood cells using a HPLC method as described previously by Ford and colleagues. 15, 16 Blood samples for TPMT enzyme activity measurement were collected 1 week before thiopurine initiation and were immediately stored at À80°C until required. TPMT enzyme activity measurement was performed after the follow-up period of 20 weeks. 12 
Data analysis
Descriptive data analysis was performed by percentages for categorical variables and by median values and ranges for continuous characteristics. Box-and-whisker plots served for visual presentation. Differences in patient characteristics were evaluated using Pearson Chi-square test; for differences in metabolite concentrations the Mann-Whitney U-test or Kolmogorov-Smirnov Z test were applied, when appropriate. P < 0.05 (two-sided) were considered to be statistically significant. SPSS for Windows (SPSS Inc., Chicago, IL, USA) software version 20.0 was used for data analysis.
The predictive threshold value of the thiopurine metabolites on the occurrence of hepatotoxicity was evaluated in patients on stable thiopurine dose. Patients with thiopurine dose adjustments or who discontinued thiopurine therapy during the follow-up period not related to hepatotoxicity were excluded from analysis. To explore the discriminative power of 6-MMPR levels regarding hepatotoxicity receiver operating characteristic (ROC) curves were generated, which plot sensitivity and false positive rates (1 À specificity). The area under the ROC curve (AUC) and 95% confidence interval (95% CI) were used to assess the predictive performance.
The predictive power of the metabolites for the occurrence of hepatotoxicity was also studied by logistic regression modelling taking possible predictors into account such as age, gender, disease type (CD/UC), body weight/body mass index (BMI) and IBD medication [systemic corticosteroids, thiopurine type, thiopurine dose and concurrent use of drugs interfering with thiopurine metabolism (i.e. mesalazine), anti-TNF therapy (infliximab, adalimumab), when appropriate]. The results are expressed as odds ratios (OR) with 95% CI.
Ethics approval
The study protocol was approved by the Institutional Review Board of the Radboud University Medical Center (Commissie Mensgebonden Onderzoek Regio Arnhem Nijmegen, protocol number: 13171), approval for inclusion of patients in other institutes was obtained from the institutional ethics committees.
RESULTS
Patient population
In total, 270 IBD patients (117 male, 153 female) with a median age of 40 years (range 19-81) were included. Baseline patient characteristics of the study population are presented in Table 1 .
Thiopurine-related adverse drug events Eighty-six of 270 patients (32%) discontinued thiopurine therapy within the first 5 months due to thiopurine intolerance or ADRs, of whom 84% (72 of 86) discontinued within the first 8 weeks. The median time of thiopurine withdrawal was 4 weeks . No difference in thiopurine withdrawal rate was observed between patients treated with MP and AZA (P = 0.142).
During the follow-up period, 47 patients (17%) developed hepatotoxicity after a median period of 4 weeks . All patients showed serum ALT elevations of >2N and in three of these patients a ratio of ALT/ALP ≥5 was found. Forty-four of these patients showed an elevation of serum aspartate transaminase of >2N.
In 40 of 47 patients (85%), signs of hepatotoxicity were observed within the first 8 weeks after thiopurine initiation.
One hundred and thirty of 270 patients (48%) reported gastrointestinal complaints: 40% of patients reported nausea, 15% vomiting and 21% anorexia. Seventy-three patients (27%) reported general malaise during the follow-up period. Concomitant treatment of systemic corticosteroids, mesalazine and anti-TNF agents (i.e. infliximab, adalimumab) did not affect 6-MMPR concentrations at week 1.
Thiopurine-induced hepatotoxicity
Hepatotoxicity was more frequently observed in patients treated with MP, compared to AZA [OR 2.1 (95% CI: 1.1-4.1)]. Comparison of patients with and without hepatotoxicity showed that age, bodyweight (T 0 ), body mass index (BMI) and MP dose were higher in the hepatotoxicity group. Furthermore, hepatotoxicity occurred more frequently in males than in females (P = 0.005). Concomitant anti-TNF therapy, mesalazine or systemic corticosteroid treatment did not affect hepatotoxicity rates (Table 1) .
Median 6-MMPR metabolite levels at week 1 were significantly higher in patients who developed hepatotoxicity compared to patients who did not: 3111 (300-15 691) vs. 1811 (300-11 230) pmol/8 9 10 8 RBCs, respectively (P < 0.001, Figure 2 ); 6-TGN metabolite concentrations did not differ between the both groups [147 (40-454) vs. 154 (40-607) pmol/8 9 10 8 RBCs respectively (P = 0.952)). TPMT enzyme activity was comparable between both patient groups (P = 0.698).
The predictive value of 6-MMPR at week 1 for hepatotoxicity was assessed for patients on stable thiopurine dose ( Figure 1 ). Forty-five of the 174 patients on stable dose developed hepatotoxicity during week 1-20.
The AUC of the continuous 6-MMPR concentration for the occurrence of hepatotoxicity was 0.65 (95% CI: 0.55-0.75; P = 0.002).
On the basis of quartile analysis of T1 6-MMPR concentrations, we defined a 6-MMPR threshold value of 3615 pmol/8 9 10 8 RBCs to predict hepatotoxicity, using the lower limit of the upper quartile (75th percentile). The associated specificity and sensitivity rates for hepatotoxicity were 84% and 42% respectively. At the T1 6-MMPR threshold of 3615 pmol/8 9 10 The area under the ROC curve of T1 6-MMPR threshold level for hepatotoxicity development was 0.63 (95% CI: 0.53-0.73, P = 0.010). When all 270 patients were evaluated, the AUC was 0.61 (0.52-0.71, P = 0.016) and OR 2.9 (95% CI: 1.5-5.7; P = 0.001).
Multivariable prediction model for thiopurine-induced hepatotoxicity Univariate regression analysis of patients on stable thiopurine therapy showed that age, gender, bodyweight and AZA, azathioprine; MP, mercaptopurine; T 0 , week 0 (baseline); TPMT, thiopurine S-methyltransferase; 6-MTG, 6-methyltioguanine. * refers to the analysis of CD and UC patients (excluding one patient with indeterminate colitis from analysis).
BMI at baseline and thiopurine type were relevant determinants for the development of hepatotoxicity. Age and BMI appeared to be the best discriminative parameters showing an AUC of 0.75 (95% CI: 0.67-0.83; P < 0.001) and 0.76 (95% CI: 0.68-0.84; P < 0.001), respectively. Next, age was dichotomised at 50 years (median value of the hepatotoxicity group) and BMI at 25 kg/m 2 to distinguish normal weight from overweight. Multivariable regression analysis of age >50 years, BMI >25 kg/ m 2 , male gender and the T1 6-MMPR threshold parameter >3615 pmol yielded ORs and predictive characteristics for the development of hepatotoxicity as presented in Table 2 .
The AUC for the obtained predicted probabilities was 0.81 (95% CI: 0.74-0.89; P < 0.00001), when including the four predictors. Figure 3 presents the ROC curves for different variables applied as predictors, such as the continuous 6-MMPR concentrations, the predictive 6-MMPR threshold and combinations of the four relevant determinants for the development of thiopurine-induced hepatotoxicity.
Finally, multivariable analysis was conducted based on the 16 different combinations of the four determinants, 6-MMPR threshold, age >50 years, BMI >25 and gender, which may serve as a predictive algorithm.
Males 
Gastrointestinal complaints and general malaise
In all patients (n = 270), no differences between age and bodyweight at baseline was found for patients with and without gastrointestinal complaints and general malaise. BMI (T 0 ) was higher in patients who reported gastrointestinal complaints, when compared to patients without [median 25 , respectively 23 (17-40) kg/ m 2 , P = 0.026], but not for general malaise (P = 0.071). Females reported more gastrointestinal complaints than males (OR 1.8 (95% CI: 1.1-2.9); no differences were observed between patients with CD or UC. The incidence of gastrointestinal complaints was higher in patients treated with MP, when compared to AZA (60% (52/87) vs. 43% (78/183); OR 2.0 (95% CI: 1.2-3.4), but not for general malaise (P = 0.058).
Thiopurine discontinuation rate was higher in patients who reported gastrointestinal complaints [OR 2.6 (95% CI: 1.5-4.4)] and general malaise [OR 3.4 (95% CI: 1.9-5.9)], compared to patients without these complaints.
At week 1, higher 6-MMPR levels were found in patients with gastrointestinal complaints, when compared to patients without these complaints [2599 (300-15 691) vs. 1731 (300-11 965) pmol/8 9 10
8 RBCs, P = 0.009).
6-TGN concentrations were comparable for both patient groups (P = 0.291). In addition, T1 6-MMPR levels were higher in patients who reported general malaise, compared to patients without these complaints [2480 (300-15 691) vs. 1848 (300-11 965) pmol/8 9 10 8 RBCs;
TPMT enzyme activity (T À1 ) was comparable between patients with and without gastrointestinal complaints or general malaise (P = 0.424 and P = 0.650, respectively).
Patients exceeding the defined 6-MMPR threshold of 3615 pmol/8 9 10 hepatotoxicity, based on 6-MMPR metabolite concentrations assessed at week one and the significant patientrelated determinants age, gender and BMI. Thiopurineassociated hepatotoxicity occurred in more than 80% of the cases during the first 8 weeks of treatment and strongly correlated with thiopurine withdrawal and/or reduction in thiopurine dose.
Steady-state thiopurine metabolite concentrations are generally reached after approximately 4-8 weeks of therapy.
14 In a prospective study with paediatric IBD patients, Dubinsky and colleagues reported a threefold increased risk of hepatotoxicity for steady-state 6-MMPR concentrations above 5700 pmol/8 9 10 8 RBCs. 8, 17 We demonstrated that early assessed 6-MMPR levels also correlate with an increased hepatotoxicity risk. However, the predictive power of 6-MMPR metabolite concentrations is rather poor for use in clinical practice (AUC 0.65), as hepatotoxicity also occurs in patients with lower 6-MMPR levels. Previous studies have reported similar results, indicating that thiopurine-associated hepatotoxicity is also caused by other determinants, such as the duration of exposure to high 6-MMPR levels or idiosyncratic reactions. 7, 8, 17, 18 In general, the most common susceptibility factors contributing to drug-induced hepatotoxicity are age (>60 year) and genetic variability. In addition, obesity, alcohol and malnutrition may deplete the hepatoprotective antioxidant glutathione in hepatocytes, which may increase the susceptibility for drug-induced hepatotoxicity. 19 Except for the male gender and cytotoxic 6-MMPR metabolite concentrations, other potential risk factors for thiopurine-associated hepatotoxicity are currently unknown. 7, 8, 10 In the present study, we found that thiopurine-induced hepatotoxicity independently correlated with the patient's gender, age, bodyweight and BMI. Notably, age and BMI demonstrated the best predictive values. Combining these relevant factors in a model with the 6-MMPR levels showed good accuracy to predict hepatotoxicity (AUC 0.83). 20 Patients with hepatotoxicity often complain of various vague symptoms, including nausea, anorexia, fatigue, malaise and abdominal pain. 9, 18 Recently, it has been reported on a large long-term follow-up study that up to 80% of patients with thiopurine-induced nausea had to discontinue therapy. 5 In present study, patients who reported gastrointestinal complaints or general malaise were about three times more likely to discontinue thiopurine treatment.
Patients exceeding the T1 6-MMPR threshold were up to 2.5 times more at risk to experience gastrointestinal complaints or general malaise. Although this observation points to a dose-dependent or 6-MMPR concentration dependent character, the discriminative value is rather poor, suggesting that other causative factors play an additional role. Several remarks should be made concerning the study design and observations. First, in our study we observed a hepatotoxicity incidence of 17%, which is higher compared to previous reports on IBD patients. 6, 21 This might be explained by the fact that in these reports predefined dose escalation schedules were applied, while our patients received the full thiopurine dose directly from start. In addition, different definitions of hepatotoxicity have been used, which makes it hard to compare these studies. 7 Elevations of c-glutamyl transpeptidase and total or conjugated bilirubin were not evaluated in our study, since we aimed to focus specifically on hepatocellular injury. Second, alcohol abuse, malnutrition, steatohepatitis, nonalcoholic fatty liver disease, viral hepatitis infections and the use of other hepatotoxic drugs, herbs or dietary supplements that may play a role in liver injury were not evaluated. 18, 19 All patients who developed hepatotoxicity had normal liver tests at baseline, but it is possible that one or more of these factors may have increased the susceptibility for thiopurine-induced hepatotoxicity. 18, 19 Third, the results of the proposed predictive algorithm are based on small patient numbers (Table S1) , and therefore should be validated in a larger study population.
Gastrointestinal intolerance and hepatotoxicity were more frequently reported in patients treated with MP, when compared to AZA. Multivariable regression analysis demonstrated that thiopurine type was not an independent determinant. This finding may therefore be explained by the higher T1 6-MMPR concentrations found in patients treated with MP, despite equivalent AZA and MP dosing. Interestingly, there was no difference of MP dose (mg/kg) observed between patients with and without hepatotoxicity. These observations underline that individual thiopurine metabolism is more important than the thiopurine dose. 14 Our findings seem not to be in line with the results of previous studies reporting tolerance of MP in patients who have failed AZA treatment. [22] [23] [24] An important aspect of AZA metabolism is the possible depletion of glutathione in hepatocytes, when AZA is converted to MP and methylnitroimidazole by glutathione S-transferase in the liver. 25 In addition, methylnitroimidazole may cause AZA intolerance in a considerable group of patients, including nausea and vomiting, flu-like illness, myalgia, arthralgia, headaches and diarrhoea. 26 Consequently, individuals expressing high hepatic glutathione S-transferase enzyme activity are at increased risk for AZA-induced hepatotoxicity, but also for adverse reactions related to an excessive release of methylnitroimidazole and MP. 25, 27 This might explain that for some patients (40-90%) who failed AZA treatment due to imidazole-related or dose-dependent intolerance, MP can be a safe and effective alternative. Patients with early AZA intolerance, including gastrointestinal complaints and hepatotoxicity, should therefore be given a trial of MP before thiopurine therapy is discarded. 7, [22] [23] [24] 26 Thiopurine metabolism is complex and unpredictable due to the involvement of the great variety of metabolic enzymes. 3 The individual genetic variants in genes encoding the metabolic enzymes that have been investigated, cannot predict the majority of the adverse reactions. 12, 28 Assessment of thiopurine metabolites can be used to reveal a patients' 'ultimate phenotype'. Therapeutic drug monitoring of thiopurine metabolites is currently advocated during maintenance therapy in case of resistance to reveal nonadherence or underdosing, and in case of dose-dependent ADRs. 29, 30 The findings of the present study show that already 1 week after initiation elevated 6-MMPR metabolite concentrations can be revealed long before steady-state levels have reached.
14 Recently, we demonstrated that both T1 6-TGN and 6-MMPR correlate with the development of leukopenia in IBD patients during the first 8 weeks of treatment. Elevated 6-TGN and/or 6-MMPR metabolite levels at week 1 could explain almost 80% of the leukopenia cases, indicating that T1 measurement can be used for multiple purposes. 31 After validation and evaluation in a prospective study, the defined T1 6-MMPR threshold and the proposed predictive algorithm could be used in clinical practice to identify patients at risk for thiopurine-induced hepatotoxicity allowing early personalised treatment.
In patients at risk, intensive liver test monitoring is recommended. In clinical practice, thiopurine dose reduction is generally reserved for patients who actually have moderate-to-severe elevated transaminases, irrespective of the 6-MMPR concentrations. 7, 30 However, patients with a preferential 6-MMPR metabolism, characterised by high 6-MMPR and relatively low (suboptimal) 6-TGN metabolite levels, are pre-disposed to fail due to therapeutic nonresponse and a higher rate of adverse drug events. 4, 32 Early identification of patients with an aberrant-skewed 6-MMPR metabolism, might therefore be helpful to prevent therapeutic failure. 32 In these cases combined therapy with allopurinol and low-dose AZA or MP results in a drastic decrease of 6-MMPR and an increase of the active 6-TGN metabolite levels. 33 Long-term combination of allopurinol (100 mg/ day) with reduced thiopurine dose (to 25-33% of initial monotherapy) has been demonstrated to be a safe and well-tolerated strategy in up to 80-90% of these patients. 33, 34 Alternatively, a switch to the thiopurine analogue tioguanine (0.3 mg/kg bodyweight per day, max. 25 mg/ day) has also been proposed as a safe option in IBD patients failing to tolerate or to respond to conventional thiopurine therapy. 35 These optimising strategies seem to be suitable to prevent early thiopurine failure in patients with a skewed 6-MMPR metabolism and additional risk factors.
In general, a precautionary dose reduction can be undertaken in patients who show both elevated 6-TGN and 6-MMPR metabolite concentrations at week 1 to prevent dose-dependent toxicity.
Future studies are needed to elucidate whether these proposed personalised strategies result in a reduction in intolerable adverse reactions and thereby prevent unnecessary therapeutic failure.
In conclusion, 6-MMPR metabolite measurement 1 week after thiopurine initiation identifies patients who are at increased risk of developing thiopurine-induced hepatotoxicity, taking the significant patient-related risk factors age, gender and BMI into account. In addition, elevated 6-MMPR levels can contribute to the explanation of gastrointestinal intolerance and general malaise, the most common limiting adverse events of thiopurines.
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